» Articles » PMID: 8782463

Microsatellite Alterations in Plasma DNA of Small Cell Lung Cancer Patients

Overview
Journal Nat Med
Date 1996 Sep 1
PMID 8782463
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Microsatellite instability is an important characteristic of many tumor types especially those associated with hereditary non-polyposis colorectal carcinoma (HNPCC) syndrome. Microsatellite alterations in 50% of primary small cell lung carcinoma (SCLC) have been found. These alterations were also found in the sputum. Because neoplastic characteristics such as decreased strand stability9 and ras mutations have been found in the plasma DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients. A microsatellite alteration was present in 16 out of 21 (76%) SCLC tumors and in 15 out of 21 (71%) plasma samples. In one case, the alteration was present only in the plasma DNA. If confirmed in larger studies, microsatellite analysis of plasma DNA might constitute a new tool for tumor staging, management and, possibly, detection.

Citing Articles

Liquid biopsy in detecting early non-small cell lung cancer.

Rosell R, Santarpia M, Pedraz-Valdunciel C, Ciappina G, Aguilar A, Gimenez-Capitan A J Liq Biopsy. 2025; 1:100001.

PMID: 40027282 PMC: 11863710. DOI: 10.1016/j.jlb.2023.100001.


Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility.

Che H, Stanley K, Jatsenko T, Thienpont B, Vermeesch J Extracell Vesicles Circ Nucl Acids. 2024; 3(3):216-234.

PMID: 39697489 PMC: 11648412. DOI: 10.20517/evcna.2022.21.


Plasma Circulating Cell-free DNA in Advanced Hepatocellular Carcinoma Patients Treated With Radiation Therapy.

Kim D, Cho E, Kim J, Chie E, Kang H In Vivo. 2023; 37(5):2306-2313.

PMID: 37652507 PMC: 10500495. DOI: 10.21873/invivo.13333.


The Role of Liquid Biopsy in the Diagnosis and Prognosis of WHO Grade 4 Astrocytoma.

Halawa T, Baeesa S, Fadul M, Badahdah A, Enani M, Fathaddin A Cureus. 2023; 15(6):e41221.

PMID: 37525780 PMC: 10387356. DOI: 10.7759/cureus.41221.


Cell-Free Methylated and Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients.

Fleischhacker M, Arslan E, Reinicke D, Eisenmann S, Theil G, Kollmeier J Diagnostics (Basel). 2023; 13(13).

PMID: 37443525 PMC: 10340633. DOI: 10.3390/diagnostics13132131.